Triamcinolone aerosol. Treatment of aspirin-hypersensitive asthmatic patients.
The efficacy of triamcinolone acetonide aerosol in the management of asthma in six patients with aspirin hypersensitivity was evaluated during a one-year trial. Five patients were previously chronically dependent on systemic corticosteroids and had undergone unsuccessful trials with cromolyn sodium therapy. Substantial reduction in corticosteroid requirements was observed; in two patients, oral prednisone therapy was completely eliminated. Forced expiratory volume and flow were maintained at levels better than those recorded before triamcinolone therapy throughout the year of follow-up. No substantial side effects due to triamcinolone were observed.
D000336:Aerosols; D001241:Aspirin / Q000276:immunology*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D004342:Drug Hypersensitivity; D006801:Humans; D008168:Lung / Q000503:physiopathology; D011241:Prednisone / Q000627:therapeutic use; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000627:therapeutic use
D000336:Aerosols; D014222:Triamcinolone Acetonide; D001241:Aspirin; D011241:Prednisone